• If you are wondering whether Chemed's current share price reflects its true worth, this article walks through the numbers behind the stock so you can judge the valuation for yourself.
• Chemed closed at US$432.34, with the stock up 1.1% over the past month but down 22.5% over the last year, which may change how you think about its risk and return profile.
• Recent coverage around Chemed has focused on its role in the US healthcare sector and how investors are weighing that exposure against broader market sentiment. This backdrop helps explain why the stock has seen short term stability alongside longer term share price pressure.
• Right now, Chemed scores 5 out of 6 on our valuation checks, giving it a value score of 5. The next sections will break that down across different valuation methods, before circling back to an even more complete way to think about what the stock might be worth.

Approach 1: Chemed Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the cash the company may generate in the future and then discounting those cash flows back to today’s value.

For Chemed, the 2 Stage Free Cash Flow to Equity model starts with last twelve months Free Cash Flow of about US$385.0 million. Analyst and extrapolated projections suggest Free Cash Flow around US$320.5 million in 2026 and US$443.0 million by 2035, with interim years stepping up gradually according to the Simply Wall St assumptions.

When all those projected cash flows are discounted back, the model arrives at an estimated intrinsic value of US$688.49 per share. Compared with the recent share price of US$432.34, this model suggests Chemed trades at a 37.2% discount to that DCF estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Chemed is undervalued by 37.2%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Approach 2: Chemed Price vs Earnings

For a profitable company like Chemed, the P/E ratio is a useful way to connect what you pay for each share with the earnings the business is currently generating. It helps you see how much investors are willing to pay for every dollar of profit.

What counts as a “normal” P/E depends on how investors view the company’s growth prospects and risk. Higher expected growth or lower perceived risk can justify a higher multiple, while slower expected growth or higher risk usually points to a lower one.

Chemed currently trades on a P/E of 22.00x. That sits close to the broader Healthcare industry average P/E of 23.51x, and well below the peer group average of 63.04x. Simply Wall St’s Fair Ratio for Chemed is 22.98x, which is its proprietary estimate of what a balanced P/E might look like once factors such as earnings growth, profit margins, industry, market cap and risk are taken into account.

This Fair Ratio gives you a more tailored reference point than a simple comparison with industry or peers, because it adjusts for Chemed’s own fundamentals rather than assuming all companies deserve the same multiple. With the actual P/E of 22.00x sitting slightly below the Fair Ratio of 22.98x, the stock screens as slightly undervalued on this measure.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 21 top founder-led companies.

Upgrade Your Decision Making: Choose your Chemed Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach your own story about Chemed to the numbers by linking what you believe about its hospice exposure, Roto Rooter cash flows, margins, future earnings and risk to a financial forecast and a Fair Value. You can then compare that Fair Value with the current share price to help you decide if the stock looks attractive or expensive. These Narratives live on the Community page, update automatically as fresh news or earnings arrive, and can differ widely. For example, one investor might lean closer to the more cautious Fair Value of US$400.0 while another aligns with a more optimistic view around US$580.0, even though both are working from the same underlying data.

Do you think there's more to the story for Chemed? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.